Alzamend Neuro (ALZN) Short Interest Ratio & Short Volume $2.96 -0.04 (-1.17%) Closing price 07/3/2025 03:25 PM EasternExtended Trading$2.96 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alzamend Neuro Short Interest DataAlzamend Neuro (ALZN) has a short interest of 136,100 shares, representing 17.46% of the float (the number of shares available for trading by the public). This marks a -80.71% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 464,647 shares to cover all short positions.Current Short Interest136,100 sharesPrevious Short Interest705,700 sharesChange Vs. Previous Month-80.71%Dollar Volume Sold Short$440.96 thousandShort Interest Ratio0.1 Days to CoverLast Record DateJune 15, 2025Outstanding Shares800,000 sharesFloat Size779,700 sharesShort Percent of Float17.46%Today's Trading Volume89,378 sharesAverage Trading Volume464,647 sharesToday's Volume Vs. Average19% Short Selling Alzamend Neuro? Sign up to receive the latest short interest report for Alzamend Neuro and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALZN Short Interest Over TimeALZN Days to Cover Over TimeALZN Percentage of Float Shorted Over Time Alzamend Neuro Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/2025136,100 shares $440.96 thousand -80.7%17.5%0.1 $3.24 5/31/2025705,700 shares $2.84 million +386.0%92.0%0.5 $4.03 5/15/2025145,200 shares $477.71 thousand -18.6%18.9%1.2 $3.29 4/30/2025178,300 shares $1.06 million -20.3%2.8%0.4 $5.94 4/15/2025223,800 shares $170.09 thousand -37.6%3.5%0.6 $0.76 3/31/2025358,600 shares $340.06 thousand +196.6%5.7%1 $0.95 3/15/2025120,900 shares $81.87 thousand -47.0%1.9%0.3 $0.68 2/28/2025228,200 shares $187.12 thousand +332.2%4.4%0.6 $0.82 2/15/202552,800 shares $57.55 thousand -33.0%1.0%0.1 $1.09 1/31/202578,800 shares $89.44 thousand +6.1%1.5%0.6 $1.14 Get the Latest News and Ratings for ALZN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. 1/15/202574,300 shares $86.93 thousand +130.8%1.4%0.5 $1.17 12/31/202432,200 shares $37.35 thousand -48.8%0.6%0.2 $1.16 12/15/202462,900 shares $74.85 thousand -52.7%1.2%0.3 $1.19 11/30/2024132,900 shares $172.77 thousand -7.9%3.1%0.6 $1.30 11/15/2024144,300 shares $196.25 thousand -35.2%3.4%0.5 $1.36 10/31/2024222,500 shares $349.33 thousand -2.6%5.3%0.1 $1.57 10/15/2024228,400 shares $381.43 thousand +121.3%5.4%0.1 $1.67 9/30/2024103,200 shares $174.41 thousand +47.9%3.0%0.1 $1.69 9/15/202469,800 shares $134.71 thousand +2.8%2.4%0 $1.93 8/31/202467,900 shares $159.57 thousand +162.2%10.7%0 $2.35 8/15/202425,900 shares $50.76 thousand +50.6%4.1%0 $1.96 7/31/202417,200 shares $61.40 thousand +126.3%2.1%1 $3.57 7/15/20247,600 shares $28.35 thousand +153.3%1.3%0.7 $3.73 6/30/202429,900 shares $11.79 thousand -68.6%0.5%0.4 $0.39 6/15/202495,100 shares $43.22 thousand +65.7%1.8%1.2 $0.45 5/31/202457,400 shares $33.87 thousand -30.1%1.1%0.9 $0.59 5/15/202482,100 shares $50.90 thousand +264.9%1.7%1 $0.62 4/30/202422,500 shares $16.00 thousand +55.2%0.5%0.3 $0.71 4/15/202414,500 shares $10.75 thousand -68.0%0.3%0.3 $0.74 3/31/202445,300 shares $45.30 thousand -11.5%0.9%0.8 $1.00 3/15/202451,200 shares $47.62 thousand +13.0%1.0%0.9 $0.93 2/29/202445,300 shares $40.77 thousand +2.5%0.9%0.7 $0.90 2/15/202444,200 shares $39.02 thousand +4.5%0.9%0.8 $0.88 1/31/202442,300 shares $36.38 thousand -41.5%0.9%0.3 $0.86 1/15/202472,300 shares $70.45 thousand -2.8%1.9%0.5 $0.97 12/31/202374,400 shares $66.22 thousand -43.5%2.1%0.6 $0.89 12/15/2023131,700 shares $131.70 thousand -29.5%3.7%1 $1.00 11/30/2023186,900 shares $226.15 thousand +379.2%5.7%1.6 $1.21 11/15/202339,000 shares $58.50 thousand -18.2%1.2%0.4 $1.50 10/31/202347,700 shares $1.25 million -92.1%1.5%2.3 $26.26How to Collect Up To $5,917/mo From Trump’s Made In USA Boom (Ad)How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback. Watch Now to Learn How to Get Your First Check in 30 Days 10/15/2023602,000 shares $124.01 thousand +30.0%1.2%2.8 $0.21 9/30/2023463,200 shares $109.78 thousand +82.8%1.0%2.2 $0.24 9/15/2023253,400 shares $60.82 thousand +17.3%0.5%1.3 $0.24 8/31/2023216,000 shares $56.64 thousand -60.7%0.4%1.2 $0.26 8/15/2023549,900 shares $169.92 thousand +8.9%1.2%2.8 $0.31 7/31/2023505,200 shares $228.86 thousand +2.6%1.1%3 $0.45 7/15/2023492,500 shares $247.24 thousand +4.0%1.1%3.1 $0.50 6/30/2023473,700 shares $241.59 thousand +13.0%1.1%2.9 $0.51 6/15/2023419,400 shares $285.19 thousand -44.9%0.9%2.5 $0.68 5/31/2023761,400 shares $552.93 thousand +44.0%1.7%4.2 $0.73 5/15/2023528,600 shares $274.71 thousand -11.1%1.2%3.2 $0.52 4/30/2023594,400 shares $325.32 thousand -8.6%1.3%3.5 $0.55 4/15/2023650,500 shares $382.04 thousand +10.9%1.4%3.4 $0.59 3/31/2023586,500 shares $249.26 thousand -18.2%1.3%2.9 $0.43 3/15/2023717,000 shares $343.73 thousand -0.4%1.6%2.4 $0.48 2/28/2023719,600 shares $386.35 thousand +5.1%1.6%2.4 $0.54 2/15/2023685,000 shares $401.48 thousand -31.1%1.5%2.2 $0.59 1/31/2023994,100 shares $659.78 thousand +11.2%2.2%2.8 $0.66 1/15/2023893,700 shares $529.96 thousand -44.8%2.0%2.5 $0.59 12/30/20221,620,000 shares $915.14 thousand +3.2%4.5%4.4 $0.56 12/15/20221,570,000 shares $1.40 million -7.7%4.4%3.6 $0.89 11/30/20221,700,000 shares $1.96 million -20.6%5.8%3.3 $1.15 11/15/20222,140,000 shares $2.40 million +27.4%7.3%4 $1.12 10/31/20221,680,000 shares $1.97 million -11.1%5.4%2.9 $1.17 10/15/20221,890,000 shares $1.98 million -34.2%5.5%3.1 $1.05 9/30/20222,870,000 shares $3.42 million +221.9%8.4%4.8 $1.19 9/15/2022891,700 shares $1.11 million -33.0%2.6%1.9 $1.24 8/31/20221,330,000 shares $1.20 million +112.9%3.9%3.7 $0.91 8/15/2022624,800 shares $649.79 thousand -40.5%1.8%1.6 $1.04 7/31/20221,050,000 shares $933.56 thousand -10.3%3.4%2.9 $0.89 7/15/20221,170,000 shares $1.09 million +17.2%4.0%2.3 $0.93 6/30/2022998,700 shares $863.28 thousand -4.9%3.5%1.4 $0.86 6/15/20221,050,000 shares $888.30 thousand -37.9%3.6%1.2 $0.85 5/31/20221,690,000 shares $1.59 million +79.0%5.8%1.4 $0.94 5/15/2022943,900 shares $884.81 thousand -41.0%2.4%0.7 $0.94 4/30/20221,600,000 shares $1.63 million +28.0%4.0%1.3 $1.02 4/15/20221,250,000 shares $1.30 million +51.0%3.2%1 $1.04 3/31/2022827,900 shares $1.02 million +83.2%2.1%0.6 $1.23 3/15/2022452,000 shares $411.32 thousand -11.1%1.2%0.3 $0.91 2/28/2022508,400 shares $594.83 thousand +2.1%1.3%0.2 $1.17 2/15/2022497,900 shares $687.10 thousand -22.1%1.3%0.1 $1.38 1/31/2022638,900 shares $977.52 thousand -73.0%1.7%0.2 $1.53 1/15/20222,370,000 shares $4.24 million +13.4%5.8%0.4 $1.79 12/31/20212,090,000 shares $3.97 million -10.3%5.2%0.3 $1.90 12/15/20212,330,000 shares $6.03 million +37.9%5.8%0.3 $2.59 11/30/20211,690,000 shares $3.62 million -39.4%4.3%0.3 $2.14 11/15/20212,790,000 shares $6.39 million +335.1%7.1%0.5 $2.29 10/29/2021641,200 shares $1.37 million +1.6%1.6%0.1 $2.14 10/15/2021631,400 shares $1.51 million +126.2%1.6%0.3 $2.39 9/30/2021279,100 shares $859.63 thousand -50.5%0.7%0.1 $3.08How to Collect Up To $5,917/mo From Trump’s Made In USA Boom (Ad)How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback. Watch Now to Learn How to Get Your First Check in 30 Days 9/15/2021563,700 shares $1.48 million +8.3%1.5%0.3 $2.63 8/31/2021520,700 shares $1.59 million +281.2%1.4%0.2 $3.06 8/13/2021136,600 shares $475.37 thousand No Change0.4%0.1 $3.48 ALZN Short Interest - Frequently Asked Questions What is Alzamend Neuro's current short interest? Short interest is the volume of Alzamend Neuro shares that have been sold short but have not yet been closed out or covered. As of June 15th, investors have sold 136,100 shares of ALZN short. 17.46% of Alzamend Neuro's shares are currently sold short. Learn More on Alzamend Neuro's current short interest. What is a good short interest percentage for Alzamend Neuro? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.46% of Alzamend Neuro's floating shares are currently sold short. Is Alzamend Neuro's short interest increasing or decreasing? Alzamend Neuro saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 136,100 shares, a decline of 80.7% from the previous total of 705,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Alzamend Neuro's float size? Alzamend Neuro currently has issued a total of 800,000 shares. Some of Alzamend Neuro's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Alzamend Neuro currently has a public float of 779,700 shares. How does Alzamend Neuro's short interest compare to its competitors? 17.46% of Alzamend Neuro's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Alzamend Neuro: LakeShore Biopharma Co., Ltd. (0.24%), Traws Pharma, Inc. (7.91%), Turnstone Biologics Corp. (2.50%), GT Biopharma, Inc. (8.50%), NLS Pharmaceutics Ltd. (3.17%), AEON Biopharma, Inc. (4.59%), Orgenesis Inc. (0.13%), Biomerica, Inc. (2.31%), Calidi Biotherapeutics, Inc. (1.23%), Chromocell Therapeutics Co. (8.70%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Alzamend Neuro stock? Short selling ALZN is an investing strategy that aims to generate trading profit from Alzamend Neuro as its price is falling. ALZN shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Alzamend Neuro? A short squeeze for Alzamend Neuro occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALZN, which in turn drives the price of the stock up even further. How often is Alzamend Neuro's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALZN, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies LakeShore Biopharma Short Interest Data Traws Pharma Short Interest Data Turnstone Biologics Short Interest Data GT Biopharma Short Interest Data NLS Pharmaceutics Short Interest Data AEON Biopharma Short Interest Data Orgenesis Short Interest Data Biomerica Short Interest Data Calidi Biotherapeutics Short Interest Data Chromocell Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALZN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
